| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $376.7M | — | +42.2% |
| Cost of Revenue | $79.2M | — | +63.7% |
| R&D Expense | $25.6M | — | +72.7% |
| SG&A Expense | $57.9M | — | +36.6% |
| Operating Income | $184.5M | — | +30.4% |
| Pre-tax Income | $180.3M | — | +25.4% |
| Income Tax | $30.3M | — | +17.7% |
| Net Income | $150.0M | — | +27.1% |
| EPS (Basic) | $1.27 | — | +32.3% |
| EPS (Diluted) | $1.22 | — | +31.2% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $309.7M | +131.5% | +75.7% |
| Accounts Receivable | $458.0M | +7.4% | +50.6% |
| Inventory | $155.5M | -11.9% | -5.7% |
| Current Assets | $1.00B | +21.5% | -20.5% |
| Total Assets | $2.67B | +5.8% | +21.7% |
| Current Liabilities | $363.2M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | $180.1M | — | +16.8% |
| Capital Expenditures | $3.7M | — | +293.8% |
| Investing Cash Flow | -$2.9M | — | +96.8% |
| Financing Cash Flow | -$1.6M | — | +51.4% |
| Free Cash Flow | $176.3M | — | +15.0% |
| +141.5% |
| Long-term Debt | $1.94B | -9.6% | +28.4% |
| Total Liabilities | $2.45B | -0.9% | +43.1% |
| Stockholders' Equity | $219.6M | +349.9% | -54.5% |